Bullfrog AI (NASDAQ:BFRG) versus Enovis (NYSE:ENOV) Head-To-Head Review

Bullfrog AI (NASDAQ:BFRG) and Enovis (NYSE:ENOV) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, dividends, risk, earnings, profitability and valuation.

Analyst Ratings

This is a summary of recent ratings and price targets for Bullfrog AI and Enovis, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bullfrog AI	1	0	0	0	1.00
Enovis	1	0	6	0	2.71

Enovis has a consensus target price of $51.17, suggesting a potential upside of 89.17%. Given Enovis’ stronger consensus rating and higher possible upside, analysts clearly believe Enovis is more favorable than Bullfrog AI.

Insider & Institutional Ownership

1.0% of Bullfrog AI shares are held by institutional investors. Comparatively, 98.5% of Enovis shares are held by institutional investors. 25.2% of Bullfrog AI shares are held by company insiders. Comparatively, 2.7% of Enovis shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Risk & Volatility

Bullfrog AI has a beta of 0.61, indicating that its stock price is 39% less volatile than the S&P 500. Comparatively, Enovis has a beta of 1.52, indicating that its stock price is 52% more volatile than the S&P 500.

Earnings & Valuation

This table compares Bullfrog AI and Enovis”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bullfrog AI	$116,670.00	110.51	-$6.99 million	($0.69)	-1.64
Enovis	$2.11 billion	0.73	-$825.49 million	($23.66)	-1.14

Bullfrog AI has higher earnings, but lower revenue than Enovis. Bullfrog AI is trading at a lower price-to-earnings ratio than Enovis, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Bullfrog AI and Enovis’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Bullfrog AI	N/A	-218.25%	-177.11%
Enovis	-61.22%	7.79%	4.00%

Summary

Enovis beats Bullfrog AI on 9 of the 14 factors compared between the two stocks.

About Bullfrog AI

Bullfrog AI Holdings, Inc., through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an analytical AI/ML platform for the analysis of preclinical and/or clinical data. It also has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for the use of a formulation of Mebendazole for the treatment of glioblastoma, and human cancer or neoplastic disease. The company was founded in 2017 and is based in Gaithersburg, Maryland.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments. Its Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals. The company's Reconstructive segment operates surgical implant business, which includes a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, as well as surgical productivity tools. The company distributes its products through independent distributors and directly under the ESAB and DJO brands. Enovis Corporation was formerly known as Colfax Corporation. The company was founded in 1995 and is headquartered in Wilmington, Delaware.